Abiraterone Improves Survival for Some Men with Hormone-Sensitive Prostate Cancer

In two large clinical trials, adding the hormone-blocking drug abiraterone to androgen-deprivation therapy (ADT) allowed men with metastatic hormone-sensitive prostate cancer to live longer than men who were treated with ADT alone.

Cancer Currents: An NCI Cancer Research Blog